CUSIP 75383L102 · who reports it, how much, and how much it matters to them
18 of the 720 hedge fund managers we track reported shares of Rapport Therapeutics, Inc. (Nasdaq: RAPP) on Form 13F for 30 June 2026. Between them they reported USD 420m. The largest position belongs to Cormorant Asset Management, at USD 111m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Cormorant Asset Management1 fund on PPLI.com | USD 111m | 5.7% |
| 2 | Sofinnova Investments1 fund on PPLI.com | USD 79m | 4.1% |
| 3 | Polar Capital LLP26 funds on PPLI.com | USD 67m | 0.2% |
| 4 | Baker Bros. Advisors2 funds on PPLI.com | USD 64m | 0.3% |
| 5 | Perceptive Advisors6 funds on PPLI.com | USD 32m | 0.5% |
| 6 | Sio Capital Management4 funds on PPLI.com | USD 13m | 2.1% |
| 7 | Burkehill Global Management5 funds on PPLI.com | USD 10m | 0.4% |
| 8 | D. E. Shaw & Co.15 funds on PPLI.com | USD 9m | 0.0% |
| 9 | Millennium Management6 funds on PPLI.com | USD 6.5m | 0.0% |
| 10 | Adage Capital Management1 fund on PPLI.com | USD 6.3m | 0.0% |
| 11 | Artia Global Partners1 fund on PPLI.com | USD 5.8m | 1.1% |
| 12 | Walleye Capital8 funds on PPLI.com | USD 4.3m | 0.0% |
| 13 | Citadel Advisors32 funds on PPLI.com | USD 3.4m | 0.0% |
| 14 | Orbimed Advisors1 fund on PPLI.com | USD 3.2m | 0.1% |
| 15 | Dafna Capital Management6 funds on PPLI.com | USD 3.1m | 0.6% |
| 16 | Two Sigma Investments35 funds on PPLI.com | USD 1m | 0.0% |
| 17 | Engineers Gate Manager1 fund on PPLI.com | USD 888,000 | 0.0% |
| 18 | Aquatic Capital Management3 funds on PPLI.com | USD 88,007 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Cormorant Asset Management | USD 111m | 5.7% |
| 2 | Sofinnova Investments | USD 79m | 4.1% |
| 3 | Sio Capital Management | USD 13m | 2.1% |
| 4 | Artia Global Partners | USD 5.8m | 1.1% |
| 5 | Dafna Capital Management | USD 3.1m | 0.6% |
| 6 | Perceptive Advisors | USD 32m | 0.5% |
| 7 | Burkehill Global Management | USD 10m | 0.4% |
| 8 | Baker Bros. Advisors | USD 64m | 0.3% |
| 9 | Polar Capital LLP | USD 67m | 0.2% |
| 10 | Orbimed Advisors | USD 3.2m | 0.1% |
Rapport Therapeutics, Inc. trades under the symbol RAPP on the Nasdaq. Its CUSIP, the code used on Form 13F, is 75383L102.
18 of the 720 hedge fund managers PPLI.com tracks reported Rapport Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Cormorant Asset Management (USD 111m), Sofinnova Investments (USD 79m), Polar Capital LLP (USD 67m), Baker Bros. Advisors (USD 64m) and Perceptive Advisors (USD 32m).
18 managers in our coverage reported it, and between them they run 154 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Cormorant Asset Management, where the position was 5.7% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Rapport Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.